Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.
about
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune ComplexesBiologic efficacy optimization--a step towards personalized medicineImmunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practiceAnti-infective immunoadhesins from plants.Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuationDC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice.Current status and future prospects for biologic treatments of psoriasis.Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera.Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.Establishment of a cell model for screening antibody drugs against rheumatoid arthritis with ADCC and CDC.Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockersClinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events.Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations.Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation.Adalimumab: a review of its use in the treatment of patients with ulcerative colitis.Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?Antidrug antibodies in psoriasis: a systematic review.Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies.Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies.Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumabImpact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study.Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization.
P2860
Q26766424-C4C9F581-9EB7-426B-BB5F-E89473F53B46Q26783657-D098F6D1-8B3A-49A5-A267-6FE0979146B6Q26798357-3D69ECF8-B5AD-44F6-BE97-8DD87616359EQ26799080-E252CCC9-9B23-4F10-B89D-D3B5D37504A6Q30235581-FEC653EE-244F-4C49-8BFA-579F4F4244D5Q30240229-376BBD2D-AE4C-477B-98DA-129895526855Q30357905-836A9E35-24F4-4BA5-AC92-A17208133E48Q33881234-0E009BC1-FF51-462D-ADD2-502B02BD467CQ34669637-BA0FC779-08BB-4E5C-A98B-0EB5B04936B5Q35843248-B96921BC-5476-4EF5-AAE3-5207EF9D7D93Q36057909-18183DE8-221A-4659-B05A-7DA9E63A7A7BQ36214720-782E648A-2F7B-43D8-9421-9372E8D88BFBQ36223471-C6B954B6-6779-4F3C-80A9-C71BC53DA71FQ36347059-81E72911-4ADB-4193-8801-1F01F3A62819Q36492612-9055E598-4CC0-4978-9376-D17806CA0074Q36776326-76D65988-3AC0-4C1D-B275-2E16D66467E8Q36832755-B8A6A968-E41A-4D75-A665-5EAAC385EA74Q37474169-3E806174-338D-485B-82F7-5939148CB497Q37517101-E80A06A9-8B08-481F-B678-BB3C15623FE1Q37562464-FC9A4ECB-6831-4890-BDAE-7F0E4EFF12F2Q37620900-B11C3B0C-E674-4C0C-89EA-B1DA129043B2Q37653421-43BBFDA6-5F10-4E26-8043-33FC35DDF6FEQ38083093-293A9355-9AA2-4092-8463-4F2A8B3EA264Q38092899-0CCB2EAB-13C6-4886-AD79-CBF5DE813BB3Q38094677-7C1BE377-F715-4B99-BB3F-720D4666DB42Q38098468-3069BFFC-4910-4614-A133-DA8DDD1D0D9BQ38150903-3B46151E-9AB5-41AC-B1E2-25AD2B77F969Q38151757-BB2490C8-4852-48A0-A742-712062A60830Q38152820-49AE9871-9446-4157-8DE0-B3C18F9B7009Q38176154-10CEB3B5-1D8E-4938-A420-B073E09D9402Q38212907-E282BA8A-0189-41AD-8B8B-CE28BB8E6A1EQ38261166-F44072E0-ED37-4FCE-900A-8720067AD710Q38445319-3E232D8A-FD33-475C-83F9-88F5A2098FAEQ38631012-1BBB4221-5B87-437B-AADD-68F64E896BC5Q38822920-4E1548AC-8DD2-4E7F-A081-F106451B4CCBQ38898145-FFC9F756-2ED9-4467-93A6-07BFFAC0B2D3Q38903708-C8CB8FB4-DB69-4837-A5D0-895A340D64E4Q38916583-935812C2-4A64-4A09-9717-2C5191326B08Q38920322-674D59DC-26CB-47EB-A137-796D735B209FQ38987484-E3680295-E67C-4A20-A2A3-52719ADA14DA
P2860
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Adalimumab elicits a restricte ...... in functional neutralisation.
@ast
Adalimumab elicits a restricte ...... in functional neutralisation.
@en
Adalimumab elicits a restricte ...... in functional neutralisation.
@nl
type
label
Adalimumab elicits a restricte ...... in functional neutralisation.
@ast
Adalimumab elicits a restricte ...... in functional neutralisation.
@en
Adalimumab elicits a restricte ...... in functional neutralisation.
@nl
prefLabel
Adalimumab elicits a restricte ...... in functional neutralisation.
@ast
Adalimumab elicits a restricte ...... in functional neutralisation.
@en
Adalimumab elicits a restricte ...... in functional neutralisation.
@nl
P2093
P1476
Adalimumab elicits a restricte ...... g in functional neutralisation
@en
P2093
Diana Wouters
Els de Groot
Esther E L van Buren
Gerrit Jan Wolbink
Lotte A van de Stadt
Lucien Aarden
Margreet Hart
S Marieke van Ham
Simone Kruithof
Theo Rispens
P304
P356
10.1136/ANNRHEUMDIS-2012-201445
P407
P577
2012-07-03T00:00:00Z